Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer

Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Frisone D, et al. Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questions. Cancer Epidemiol. 2022;80:102232.

Article  PubMed  Google Scholar 

Ganti AK, et al. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol. 2021;7(12):1824–32.

Article  PubMed  Google Scholar 

National Comprehensive Cancer Network. Guidelines for treatment of cancer by type: non-small cell lung cancer. Version 2.2022. 2022 .

Dunant A, Pignon JP, Le Chevalier T. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial. Clin Cancer Res. 2005;11(13 Pt 2):5017s–21s.

Article  CAS  PubMed  Google Scholar 

Douillard JY, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27.

Article  CAS  PubMed  Google Scholar 

Pignon JP, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–9.

Article  PubMed  Google Scholar 

Fichtner I, Tanneberger S. Preoperative (neoadjuvant) chemotherapy in the murine Lewis lung carcinoma and possible implications for clinical use. Anticancer Res. 1987;7(2):227–33.

CAS  PubMed  Google Scholar 

Einhorn LH. Neoadjuvant therapy of stage III non-small cell lung cancer. Ann Thorac Surg. 1988;46(3):362–5.

Article  CAS  PubMed  Google Scholar 

Song WA, et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J Thorac Oncol. 2010;5(4):510–6.

Article  PubMed  Google Scholar 

Felip E, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28(19):3138–45.

Article  CAS  PubMed  Google Scholar 

NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561–71.

Article  PubMed Central  Google Scholar 

Friedlaender A, et al. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. Cancer Treat Rev. 2022;104:102350.

Article  CAS  PubMed  Google Scholar 

Arakawa A, et al. Clonality of CD4. Front Immunol. 2019;10:1336.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477)

Liu J, et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016;6(12):1382–99.

Article  CAS  PubMed  Google Scholar 

Cascone T, et al. Abstract 1719: Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer. Cancer Res. 2018;78(13_Supplement):1719.

Article  Google Scholar 

McGranahan N, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Forde PM, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378(21):1976–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosner S, et al. Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2023;29(4):705–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaft JE, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022;28(10):2155–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Besse B, et al. 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial. Ann Oncol. 2020;31:S794–5.

Article  Google Scholar 

Reuss JE, et al. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020;8(2)

Cascone T, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cascone T, et al. Abstract CT011: NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC). Cancer Res. 2022;82(12_Supplement):CT011.

Article  Google Scholar 

Spicer J, et al. 929MO Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study. Ann Oncol. 2022;33:S971.

Article  Google Scholar 

Demaria S, Golden EB, Formenti SC. Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol. 2015;1(9):1325–32.

Article  PubMed  Google Scholar 

Dewan MZ, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoneda K, et al. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Br J Cancer. 2019;121(6):490–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gennen K, et al. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiat Oncol. 2020;15(1):5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee B, et al. Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non-small cell lung cancer: Results from a randomized trial. J Thorac Cardiovasc Surg. 2023;165(1):327–334.e2.

Article  PubMed  Google Scholar 

Altorki NK, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 2021;22(6):824–35.

Article  CAS  PubMed  Google Scholar 

Dickhoff C, et al. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. BMC Cancer. 2020;20(1):764.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamada A, et al. Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L). Clin Lung Cancer. 2021;22(6):596–600.

Article  CAS  PubMed  Google Scholar 

Lemmon CA, et al. A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC. JTO Clin Res Rep. 2022;3(7):100359.

PubMed  PubMed Central  Google Scholar 

Yi JS, et al. Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. Clin Cancer Res. 2017;23(24):7474–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shu CA, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):786–95.

Article  CAS  PubMed  Google Scholar 

Provencio M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1413–22.

Article  CAS  PubMed  Google Scholar 

Provencio-Pulla M, et al. Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial. J Clin Oncol. 2022;40(16_suppl):8501.

Article  Google Scholar 

FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-early-stage-non-small-cell-lung. Accessed 4 Mar 2022.

Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer [ID3757]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ta10632. Accessed 22 Mar 2023.

Lisberg A, et al. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol. 2018;13(8):1138–45.

Article 

留言 (0)

沒有登入
gif